Immunotherapy of mesothelioma: the evolving change of a long-standing therapeutic dream
Pleural mesothelioma (PM) is an aggressive and rare disease, characterized by a very poor prognosis. For almost two decades, the world standard treatment regimen for unresectable PM has consisted of a platinum-based drug plus pemetrexed, leading to an overall survival of approximately 12 months. The...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-01-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1333661/full |
| _version_ | 1797362402132492288 |
|---|---|
| author | Luana Calabrò Luana Calabrò Giuseppe Bronte Giuseppe Bronte Federica Grosso Luigi Cerbone Angelo Delmonte Fabio Nicolini Massimiliano Mazza Anna Maria Di Giacomo Anna Maria Di Giacomo Alessia Covre Alessia Covre Alessia Covre Maria Fortunata Lofiego Maria Fortunata Lofiego Maria Fortunata Lofiego Lucio Crinò Michele Maio Michele Maio Michele Maio Michele Maio |
| author_facet | Luana Calabrò Luana Calabrò Giuseppe Bronte Giuseppe Bronte Federica Grosso Luigi Cerbone Angelo Delmonte Fabio Nicolini Massimiliano Mazza Anna Maria Di Giacomo Anna Maria Di Giacomo Alessia Covre Alessia Covre Alessia Covre Maria Fortunata Lofiego Maria Fortunata Lofiego Maria Fortunata Lofiego Lucio Crinò Michele Maio Michele Maio Michele Maio Michele Maio |
| author_sort | Luana Calabrò |
| collection | DOAJ |
| description | Pleural mesothelioma (PM) is an aggressive and rare disease, characterized by a very poor prognosis. For almost two decades, the world standard treatment regimen for unresectable PM has consisted of a platinum-based drug plus pemetrexed, leading to an overall survival of approximately 12 months. The dramatic therapeutic scenario of PM has recently changed with the entry into the clinic of immune checkpoint inhibition, which has proven to be an effective approach to improve the survival of PM patients. The aim of the present review is to provide a comprehensive overview of the most promising immunotherapeutic-based strategies currently under investigation for advanced PM. |
| first_indexed | 2024-03-08T16:07:30Z |
| format | Article |
| id | doaj.art-8927fd98d7b248cbac772e012b06e713 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-03-08T16:07:30Z |
| publishDate | 2024-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-8927fd98d7b248cbac772e012b06e7132024-01-08T05:06:49ZengFrontiers Media S.A.Frontiers in Immunology1664-32242024-01-011410.3389/fimmu.2023.13336611333661Immunotherapy of mesothelioma: the evolving change of a long-standing therapeutic dreamLuana Calabrò0Luana Calabrò1Giuseppe Bronte2Giuseppe Bronte3Federica Grosso4Luigi Cerbone5Angelo Delmonte6Fabio Nicolini7Massimiliano Mazza8Anna Maria Di Giacomo9Anna Maria Di Giacomo10Alessia Covre11Alessia Covre12Alessia Covre13Maria Fortunata Lofiego14Maria Fortunata Lofiego15Maria Fortunata Lofiego16Lucio Crinò17Michele Maio18Michele Maio19Michele Maio20Michele Maio21Department of Translational Medicine, University of Ferrara, Ferrara, ItalyDepartment of Oncology, University Hospital of Ferrara, Ferrara, ItalyDepartment of Clinical and Molecular Sciences (DISCLIMO), Università Politecnica Delle Marche, Ancona, ItalyClinic of Laboratory and Precision Medicine, National Institute of Health and Sciences On Ageing (IRCCS INRCA), Ancona, ItalyMesothelioma, Melanoma and Sarcoma Unit, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria, ItalyMesothelioma, Melanoma and Sarcoma Unit, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria, ItalyDepartment of Medical Oncology, IRCCS Istituto Romagnolo Per Lo Studio Dei Tumori (IRST) “Dino Amadori”, Meldola, ItalyIRCCS Istituto Romagnolo Per Lo Studio Dei Tumori (IRST) “Dino Amadori”, Meldola, ItalyIRCCS Istituto Romagnolo Per Lo Studio Dei Tumori (IRST) “Dino Amadori”, Meldola, ItalyCenter for Immuno-Oncology, Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Siena, ItalyCenter for Immuno-Oncology, University of Siena, Siena, ItalyCenter for Immuno-Oncology, Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Siena, ItalyCenter for Immuno-Oncology, University of Siena, Siena, Italy0EPigenetic Immune-Oncology Consortium Airc (EPICA), Siena, ItalyCenter for Immuno-Oncology, Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Siena, ItalyCenter for Immuno-Oncology, University of Siena, Siena, Italy0EPigenetic Immune-Oncology Consortium Airc (EPICA), Siena, ItalyDepartment of Medical Oncology, IRCCS Istituto Romagnolo Per Lo Studio Dei Tumori (IRST) “Dino Amadori”, Meldola, ItalyCenter for Immuno-Oncology, Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Siena, ItalyCenter for Immuno-Oncology, University of Siena, Siena, Italy0EPigenetic Immune-Oncology Consortium Airc (EPICA), Siena, Italy1Fondazione Network Italiano per la Bioterapia dei Tumori (NIBIT) Onlus, Siena, ItalyPleural mesothelioma (PM) is an aggressive and rare disease, characterized by a very poor prognosis. For almost two decades, the world standard treatment regimen for unresectable PM has consisted of a platinum-based drug plus pemetrexed, leading to an overall survival of approximately 12 months. The dramatic therapeutic scenario of PM has recently changed with the entry into the clinic of immune checkpoint inhibition, which has proven to be an effective approach to improve the survival of PM patients. The aim of the present review is to provide a comprehensive overview of the most promising immunotherapeutic-based strategies currently under investigation for advanced PM.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1333661/fullpleural mesotheliomaimmunotherapyimmune checkpoint inhibitorsadoptive cell therapyepigenetic drugs |
| spellingShingle | Luana Calabrò Luana Calabrò Giuseppe Bronte Giuseppe Bronte Federica Grosso Luigi Cerbone Angelo Delmonte Fabio Nicolini Massimiliano Mazza Anna Maria Di Giacomo Anna Maria Di Giacomo Alessia Covre Alessia Covre Alessia Covre Maria Fortunata Lofiego Maria Fortunata Lofiego Maria Fortunata Lofiego Lucio Crinò Michele Maio Michele Maio Michele Maio Michele Maio Immunotherapy of mesothelioma: the evolving change of a long-standing therapeutic dream Frontiers in Immunology pleural mesothelioma immunotherapy immune checkpoint inhibitors adoptive cell therapy epigenetic drugs |
| title | Immunotherapy of mesothelioma: the evolving change of a long-standing therapeutic dream |
| title_full | Immunotherapy of mesothelioma: the evolving change of a long-standing therapeutic dream |
| title_fullStr | Immunotherapy of mesothelioma: the evolving change of a long-standing therapeutic dream |
| title_full_unstemmed | Immunotherapy of mesothelioma: the evolving change of a long-standing therapeutic dream |
| title_short | Immunotherapy of mesothelioma: the evolving change of a long-standing therapeutic dream |
| title_sort | immunotherapy of mesothelioma the evolving change of a long standing therapeutic dream |
| topic | pleural mesothelioma immunotherapy immune checkpoint inhibitors adoptive cell therapy epigenetic drugs |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1333661/full |
| work_keys_str_mv | AT luanacalabro immunotherapyofmesotheliomatheevolvingchangeofalongstandingtherapeuticdream AT luanacalabro immunotherapyofmesotheliomatheevolvingchangeofalongstandingtherapeuticdream AT giuseppebronte immunotherapyofmesotheliomatheevolvingchangeofalongstandingtherapeuticdream AT giuseppebronte immunotherapyofmesotheliomatheevolvingchangeofalongstandingtherapeuticdream AT federicagrosso immunotherapyofmesotheliomatheevolvingchangeofalongstandingtherapeuticdream AT luigicerbone immunotherapyofmesotheliomatheevolvingchangeofalongstandingtherapeuticdream AT angelodelmonte immunotherapyofmesotheliomatheevolvingchangeofalongstandingtherapeuticdream AT fabionicolini immunotherapyofmesotheliomatheevolvingchangeofalongstandingtherapeuticdream AT massimilianomazza immunotherapyofmesotheliomatheevolvingchangeofalongstandingtherapeuticdream AT annamariadigiacomo immunotherapyofmesotheliomatheevolvingchangeofalongstandingtherapeuticdream AT annamariadigiacomo immunotherapyofmesotheliomatheevolvingchangeofalongstandingtherapeuticdream AT alessiacovre immunotherapyofmesotheliomatheevolvingchangeofalongstandingtherapeuticdream AT alessiacovre immunotherapyofmesotheliomatheevolvingchangeofalongstandingtherapeuticdream AT alessiacovre immunotherapyofmesotheliomatheevolvingchangeofalongstandingtherapeuticdream AT mariafortunatalofiego immunotherapyofmesotheliomatheevolvingchangeofalongstandingtherapeuticdream AT mariafortunatalofiego immunotherapyofmesotheliomatheevolvingchangeofalongstandingtherapeuticdream AT mariafortunatalofiego immunotherapyofmesotheliomatheevolvingchangeofalongstandingtherapeuticdream AT luciocrino immunotherapyofmesotheliomatheevolvingchangeofalongstandingtherapeuticdream AT michelemaio immunotherapyofmesotheliomatheevolvingchangeofalongstandingtherapeuticdream AT michelemaio immunotherapyofmesotheliomatheevolvingchangeofalongstandingtherapeuticdream AT michelemaio immunotherapyofmesotheliomatheevolvingchangeofalongstandingtherapeuticdream AT michelemaio immunotherapyofmesotheliomatheevolvingchangeofalongstandingtherapeuticdream |